File Download

There are no files associated with this item.

Supplementary

Conference Paper: Risk assessment of hereditary breast and ovarian cancer syndrome in Chinese population by multiple-gene sequencing

TitleRisk assessment of hereditary breast and ovarian cancer syndrome in Chinese population by multiple-gene sequencing
Authors
Issue Date2021
PublisherFood and Health Bureau, HKSAR.
Citation
Health Research Symposium 2021: Implementing evidence-based research in the era of COVID-19 and other global health challenges, Hong Kong, 23 November 2021 How to Cite?
AbstractDifferences in the mutation spectrum across ethnicities suggest that it is important to identify genes in addition to common high penetrant genes to estimate the associated breast cancer risk in Chinese. A total of 1,338 high-risk breast cancer patients who tested negative for germline BRCA1, BRCA2, TP53 and PTEN mutations between 2007-2017 were selected from the Hong Kong Hereditary Breast Cancer Family Registry. Patient samples were subjected to next-generation DNA sequencing using a multigene panel. All detected pathogenic variants were validated by bi-directional DNA sequencing. The sequencing data was co-analyzed by our in-house developed bioinformatics pipeline. Sixty-one pathogenic variants (4.6%) were identified in 11 cancer predisposition genes. The majority of the carriers (77.1%) had early-onset of breast cancer (age <45), 32.8% had family members with breast cancer and 11.5% had triple-negative breast cancer (TNBC). The most common mutated genes were PALB2 (1.4%), RAD51D (0.8%) and ATM (0.8%). A total of 612 variants of unknown significance (VUS) were identified in 494 patients, and 87.4% of the VUS were missense mutations. An additional 4.6% of the patients were identified in patients who tested negative for germline BRCA1, BRCA2, TP53 and PTEN mutations using the multigene test panel.
DescriptionOral Presentation - Parallel Session 2: Implementing Research Findings in Clinical Practice - abstract no. T2c
Persistent Identifierhttp://hdl.handle.net/10722/312240

 

DC FieldValueLanguage
dc.contributor.authorKwong, A-
dc.contributor.authorShin, VY-
dc.contributor.authorChen, J-
dc.contributor.authorCheuk, WYI-
dc.contributor.authorHo, YSC-
dc.contributor.authorAu, CH-
dc.contributor.authorChan, KKL-
dc.contributor.authorNgan, HYS-
dc.contributor.authorChan, TL-
dc.contributor.authorFord, JM-
dc.contributor.authorMa, ESK-
dc.date.accessioned2022-04-25T01:37:04Z-
dc.date.available2022-04-25T01:37:04Z-
dc.date.issued2021-
dc.identifier.citationHealth Research Symposium 2021: Implementing evidence-based research in the era of COVID-19 and other global health challenges, Hong Kong, 23 November 2021-
dc.identifier.urihttp://hdl.handle.net/10722/312240-
dc.descriptionOral Presentation - Parallel Session 2: Implementing Research Findings in Clinical Practice - abstract no. T2c-
dc.description.abstractDifferences in the mutation spectrum across ethnicities suggest that it is important to identify genes in addition to common high penetrant genes to estimate the associated breast cancer risk in Chinese. A total of 1,338 high-risk breast cancer patients who tested negative for germline BRCA1, BRCA2, TP53 and PTEN mutations between 2007-2017 were selected from the Hong Kong Hereditary Breast Cancer Family Registry. Patient samples were subjected to next-generation DNA sequencing using a multigene panel. All detected pathogenic variants were validated by bi-directional DNA sequencing. The sequencing data was co-analyzed by our in-house developed bioinformatics pipeline. Sixty-one pathogenic variants (4.6%) were identified in 11 cancer predisposition genes. The majority of the carriers (77.1%) had early-onset of breast cancer (age <45), 32.8% had family members with breast cancer and 11.5% had triple-negative breast cancer (TNBC). The most common mutated genes were PALB2 (1.4%), RAD51D (0.8%) and ATM (0.8%). A total of 612 variants of unknown significance (VUS) were identified in 494 patients, and 87.4% of the VUS were missense mutations. An additional 4.6% of the patients were identified in patients who tested negative for germline BRCA1, BRCA2, TP53 and PTEN mutations using the multigene test panel.-
dc.languageeng-
dc.publisherFood and Health Bureau, HKSAR. -
dc.relation.ispartofHealth Research Symposium 2021-
dc.titleRisk assessment of hereditary breast and ovarian cancer syndrome in Chinese population by multiple-gene sequencing-
dc.typeConference_Paper-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.emailShin, VY: vyshin@hku.hk-
dc.identifier.emailChan, KKL: kklchan@hkucc.hku.hk-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.authorityShin, VY=rp02000-
dc.identifier.authorityChan, KKL=rp00499-
dc.identifier.authorityNgan, HYS=rp00346-
dc.identifier.authorityChan, TL=rp00418-
dc.identifier.hkuros332780-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats